Skip to main content
. 2017 Mar 13;36(28):3986–4000. doi: 10.1038/onc.2017.29

Figure 2.

Figure 2

miR-377 inhibited TIC properties. (a) KYSE270 cells (left panel) and T.Tn cells (right panel) with ectopic miR-377 expression and corresponding control cells were treated with 5-FU (5 μM), DDP (20 μM) or DMSO for 72 h, and cell viability compared using MTT assay. (b) Sphere-forming ESCC cells and differentiated adherent counterparts were compared for miR-377 expression by qRT–PCR. (c) Sphere formation ability of KYSE270 and T.Tn cells transfected with 50 nm miR-377 mimic (left panel), or 0.8 μg miR-377 expressing plasmid (right panel) was compared with corresponding controls. (d) Growth curves of subcutaneous tumors formed by KYSE150-miR-377 cells (left panel) and KYSE270-miR-377 cells (right panel) compared with respective control cells expressing miR-CON (n=6/group). Bars, s.d.; *P<0.05; **P<0.01; ***P<0.001 compared with controls.